Pasireotide
Pasireotide is an injectable somatostatin analogue used primarily to treat Cushing's disease when surgery is not an option or has been unsuccessful. It works by binding to somatostatin receptors to reduce excess hormone production, particularly cortisol, helping to control the symptoms associated with this condition.
Pasireotide is a somatostatin analogue injection that treats Cushing's disease by reducing cortisol production through binding to somatostatin receptors.
Key facts at a glance
- ATC
- H01CB05
- RxNorm
- 1364105
- Generic
- Pasireotide
- Class
- atc-h01
- Brands
- Signifor
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 500mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 250mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 400mg daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
12 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless potential benefits justify potential risks to the fetus
regular fetal monitoring and ultrasound assessments
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
second trimesteravoid if possible
continue treatment only if clearly needed with careful risk-benefit assessment
fetal growth monitoring and regular prenatal care
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
third trimesteravoid if possible
discontinue treatment if pregnancy occurs unless benefits outweigh risks
fetal monitoring and assessment of fetal well-being
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
breastfeedingnot applicable
breastfeeding is not recommended during pasireotide treatment due to unknown excretion in breast milk
monitor infant for any adverse effects if breastfeeding continues
geriatric
elderly 65 and olderno specific dose adjustment required
use with caution and monitor for adverse effects; start at lower end of dosing range
regular monitoring of liver function and electrolytes
Use with caution and monitor for adverse effects.
pediatric_age
pediatric under 18not recommended
pasireotide is not recommended for use in pediatric patients; safety and efficacy not established in patients under 18 years of age
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
renal_impairment
mild renal impairmentno dose adjustment required
no dose adjustment needed for mild renal impairment
standard monitoring
renal_impairment
moderate renal impairmentno specific adjustment required
use with caution; monitor renal function regularly
regular monitoring of renal function and electrolytes
Use with caution and monitor for adverse effects.
renal_impairment
severe renal impairmentuse with caution
use pasireotide with caution in severe renal impairment; no specific dose adjustment established
frequent monitoring of renal function and potential drug accumulation
Use with caution and monitor for adverse effects.
hepatic_impairment
mild hepatic impairmentno dose adjustment required
no dose adjustment needed for mild hepatic impairment
standard monitoring
hepatic_impairment
moderate hepatic impairmentdose reduction recommended
reduce starting dose in patients with moderate hepatic impairment (Child-Pugh B)
regular monitoring of liver function and drug exposure
Use with caution and monitor for adverse effects.
hepatic_impairment
severe hepatic impairmentnot recommended
pasireotide is not recommended for use in patients with severe hepatic impairment (Child-Pugh C)
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
Statistics and clinical data
Drug class
Drug class information for Pasireotide
FDA approval year (Cushing's disease)
FDA approval for Cushing's disease
Common uses
Primary therapeutic indications
Route of administration
Method of drug administration
Treatment of Cushing's disease (endogenous hypercortisolism) in adult patients for whom surgery is not an option or has not been curative. It may also be used for acromegaly in certain patients.
Pasireotide is a cyclohexapeptide somatostatin analogue that binds to somatostatin receptors (SSTR 1-5), mimicking the natural hormone somatostatin to inhibit excessive hormone secretion, particularly reducing cortisol production from the pituitary gland.
Administered by subcutaneous injection, typically twice daily. Common side effects include hyperglycemia, diarrhea, nausea, and gallbladder abnormalities. Regular monitoring of blood glucose, liver function, and cortisol levels is recommended. May cause QT prolongation in some patients.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy